Series C - Cyteir Therapeutics
Investment Firm
Overview
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Announced Date
Feb 11, 2021
Funding Type
Series C
Highlights
Location
United States, North America
Social
Investor Lead
RA Capital Management
RA Capital Management is a convertible_note and debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.
Ally Bridge Group
Ally Bridge Group is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.
Avidity Partners
Avidity Partners is a early_stage_venture and late_stage_venture firm.
CaaS Capital Management
CaaS Capital Management is a late_stage_venture firm.
Participant Investors
9
Round Details and Background
Cyteir Therapeutics raised $80000000 on 2021-02-11 in Series C
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Company Funding History
5
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Oct 15, 2019 |  Series B - Cyteir Therapeutics | 6 | - | 40.2M |
| Feb 11, 2021 | Series C - Cyteir Therapeutics | 12 | - | 80.0M |
| Jun 29, 2016 | Grant - Cyteir Therapeutics | 1 | - | 2.0M |
| Nov 05, 2015 | Series A - Cyteir Therapeutics | 1 | - | 5.5M |
Recent Activity
There is no recent news or activity for this profile.